## Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application: Listing of Claims:

1. (Previously presented): A compound of formula (I)

$$\mathbb{R}^{b} \xrightarrow{\mathbb{N}^{b}} \mathbb{N}$$

or a pharmaceutically acceptable salt thereof wherein:

Ra and Rb are, independently:

- (i) hydrogen:
- (ii) acetyl;
- (iii) -(C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally, and independently, substituted with from 1-3 of:

(a) halogen; (b) -NR<sup>2</sup>R<sup>4</sup>; (c) -COR<sup>5</sup>, (d) -OR<sup>6</sup>, (e) aryl, optionally, and independently, substituted with from 1-3 of halogen; -(C<sub>1</sub>-C<sub>0</sub>)alkyt; or -(C<sub>1</sub>-C<sub>0</sub>)alkoxy; (f) heteroaryl, optionally, and independently, substituted with from 1-3 of trifluoromethyl or -(C<sub>1</sub>-C<sub>0</sub>)alkyl; (g) -(C<sub>2</sub>-C<sub>11</sub>)cycloalkyl; or (h) -(C<sub>2</sub>-C<sub>11</sub>)heterocycloalkyl, optionally, and independently, substituted with from 1-3 of -(C<sub>1</sub>-C<sub>0</sub>)alkoyt or -(C<sub>1</sub>-C<sub>0</sub>)alkoyt, wherein:

R3 and R4 are independently:

(j) hydrogen; (k) amidino; (l) aryl, optionally, and independently, substituted with from 1-3 of halogen; cyano; nitro; -(C<sub>1</sub>-C<sub>0</sub>)alkyl, -(C<sub>1</sub>-C<sub>0</sub>)alkoy, or -COR<sup>8</sup>; (m) -(C<sub>1</sub>-C<sub>0</sub>-galkyl, optionally, and independently, substituted with from 1-3 of -(C<sub>3</sub>-C<sub>11</sub>)heterocycloalkyl; -(C<sub>3</sub>-C<sub>0</sub>)alkyl, -(C<sub>1</sub>-C<sub>0</sub>)alkoxy, aryl; or heteroaryl; (n) heteroaryl, optionally, and independently, substituted with from 1-3 of halogen; trifluoromethyl; cyano; nitro; -COR<sup>5</sup>; -(C<sub>1</sub>-C<sub>0</sub>)alkyl, optionally substituted with -(C<sub>3</sub>-C<sub>11</sub>)heterocycloalkyl; or -(C<sub>1</sub>-C<sub>0</sub>)alkoxy; (o) -(C<sub>3</sub>-C<sub>11</sub>)heterocycloalkyl, optionally substituted with from 1-3 of -(C<sub>1</sub>-C<sub>0</sub>)alkyl; or (p) -COR<sup>8</sup>;

 $R^{5} \text{ is (q) hydroxy; (r) -(C_{1}\text{-}C_{e})alkyl, optionally, and independently, substituted with from 1-3} \\ \text{of -(C_{1}\text{-}C_{e})alkoxy or aryl; (s) -(C_{1}\text{-}C_{e})alkoxy; (t) heteroaryl; or (u) -(C_{3}\text{-}C_{11})heterocycloalkyl, optionally substituted with from 1-3 of -(C_{1}\text{-}C_{e})alkyl; and }$ 

 $R^{6}$  is (v) -( $C_{1}$ - $C_{0}$ )alkyl, optionally, and independently, substituted with from 1-3 of -( $C_{1}$ - $C_{0}$ )alkoxy or aryl; (w) heteroaryl; or (x) -( $C_{3}$ - $C_{11}$ )heterocycloalkyl, optionally substituted with from 1-3 of -( $C_{1}$ - $C_{0}$ )alkyl;

(iv) -(C3-C11)cycloalkyl; or

(v) -( $C_3$ - $C_{11}$ )heterocycloalkyl, optionally, and independently, substituted with from 1-3 of halogen; - $COR^5$ ; -( $C_1$ - $C_n$ )alkyl; and -( $C_1$ - $C_n$ )alkoxy; or

 $R^a$  and  $R^b$ , taken together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, optionally having from 1-3 additional heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said 5- or 6-membered heterocycloalkyl ring is optionally, and independently, substituted with from 1-3 of halogen; -( $C_1$ - $C_0$ )alkyl; or heteroaryl, optionally, and independently, substituted with from 1-3 of halogen; riftlipromethyl; and cvano; and

R<sup>1</sup> and R<sup>2</sup> are independently selected from the group consisting of amino; halogen; hydrogen; trifluoromethyl; nitro; -COR<sup>5</sup>; -NR<sup>3</sup>R<sup>4</sup>; -CONR<sup>3</sup>R<sup>4</sup>; and -(C<sub>1</sub>-C<sub>8</sub>)alkyl, optionally, and independently, substituted with from 1-3 of -(C<sub>3</sub>-C<sub>11</sub>)heterocycloalkyl; -NR<sup>3</sup>R<sup>4</sup>; aryl; heteroaryl; or hydroxy;

provided when R<sup>a</sup> is hydrogen, and R<sup>b</sup> is hydrogen or isopropyl, R<sup>1</sup> is not halogen.

## 2. (Previously presented) The compound of claim 1, wherein:

Ra is hydrogen;

 $R^b$  is selected from the group consisting of (iii)  $\neg (C_1 \neg C_0)$ alkyl, optionally substituted with: (b)- $NR^3R^3$ , wherein  $R^3$  is hydrogen and  $R^4$  is heteroaryl, optionally, and independently, substituted with from 1-3 of trifluoromethyl; cyano;  $\neg (C_1 \neg C_0)$ alkyl, optionally substituted with  $\neg (C_2 \neg C_1)$ heterocycloalkyl;  $\neg (C_1 \neg C_0)$ alkoxy; or  $\neg COR^{25}$ ; (e) aryl, optionally substituted with from 1-3 halogen atoms; (f) heteroaryl; (h)  $\neg (C_2 \neg C_1)$ heterocycloalkyl; (iv)  $\neg (C_2 \neg C_1)$ heterocycloalkyl; (iv)  $\neg (C_2 \neg C_1)$ heterocycloalkyl; (iv)

R<sup>1</sup> is hydrogen; halogen; -COR<sup>5</sup>, -CONR<sup>3</sup>R<sup>4</sup>; or -(C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally, and independently, substituted with from 1-3 of -(C<sub>2</sub>-C<sub>1</sub>-1)heterocycloalkyl or -NR<sup>3</sup>R<sup>4</sup>: and

R<sup>2</sup> is hydrogen; -CONR<sup>3</sup>R<sup>4</sup>, or -(C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally, and independently, substituted with from 1-3 of -(C<sub>2</sub>-C<sub>11</sub>)heterocycloalkyl or -NR<sup>3</sup>R<sup>4</sup>.

## 3. (Previously presented) The compound of claim 1, wherein:

Ra is hydrogen;

R<sup>b</sup> is (iii) -(C<sub>1</sub>-C<sub>3</sub>)alkyl, optionally substituted with (b) -NR<sup>2</sup>R<sup>4</sup>, wherein R<sup>3</sup> is hydrogen and R<sup>4</sup> is heteroaryl, optionally, and independently, substituted with from 1-3 of trifluoromethyl; cyano; -

 $(C_1-C_0)$ alkyl, optionally substituted with  $-(C_3-C_{11})$ heterocycloalkyl; or  $-(C_1-C_0)$ alkoxy; (e) aryl; (f) heteroaryl; (h)  $-(C_3-C_0)$ heterocycloalkyl; (iv)  $-(C_3-C_0)$ cycloalkyl; or (v)  $-(C_3-C_{11})$ heterocycloalkyl;

 $R^1$  is hydrogen; fluoro; chloro; bromo; -COR $^5$ , wherein  $R^5$  is hydroxy or -( $C_1$ - $C_0$ )alkoxy; or -CONR $^3$ R $^4$ , wherein  $R^3$  is hydrogen or -( $C_1$ - $C_0$ )alkyl; and  $R^4$  is -( $C_1$ - $C_0$ )alkyl, optionally substituted with -( $C_1$ - $C_0$ )alkoxy; and

 $R^2 \ \text{is hydrogen or -CONR}^3 R^4, \ \text{wherein R}^3 \ \text{is -(C}_1\text{-C}_6) \text{alkyl; and R}^4 \ \text{is -(C}_1\text{-C}_6) \text{alkyl, optionally substituted with -(C}_1\text{-C}_6) \text{alkoxy.}$ 

4. (Previously presented) The compound of claim 1 selected from the group consisting of:

8-fluoro-4-cyclohexyllamino-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

8-fluoro-4-(piperidin-4-ylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

8-fluoro-4-(4-phenyl-propylamino)-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

4-isopropylamino-1-oxo-1,2-dihydro-[1,2,4]triazolo[4,3-a]quinoxalin-8-carboxylic acid-(2-methoxy-ethyl)-amide:

4-isopropylamino-1-oxo-1,2-dihydro-[1,2,4]triazolo[4,3-a]quinoxalin-8-carboxylic acid-dimethylamide;

4-isopropylamino-1-oxo-1,2-dihydro-[1,2,4]triazolo[4,3-a]quinoxalin-7-carboxylic acidmethylamide;

4-isopropylamino-1-oxo-1,2-dihydro-[1,2,4]triazolo[4,3-a]quinoxalin-8-carboxylic acid-isobutyl amide;

4-isopropylamino-1-oxo-1,2-dihydro-[1,2,4]triazolo[4,3-a]quinoxalin-7-carboxylic acid-(2-methoxy-ethyl)-methyl amide;

4-isopropylamino-1-oxo-1,2-dihydro-[1,2,4]triazolo[4,3-a]quinoxalin-8-carboxylic acid, sodium salt;

4-[2-(1H-benzoimidazol-2-yl)-butylamino]-8-fluoro-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

4-[2-(1H-benzoimidazol-2-y)-ethylamino]-8-fluoro-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; 4-[2-(1H-benzoimidazol-2-vlamino)-ethylamino]-8-fluoro-2H-[1,2,4]triazolo[4,3-a]quinoxaline-

1-one;

 $\label{lem:condition} \mbox{4-[2-(benzooxazol-2-ylamino)-ethylamino]-8-chloro-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; \\ \mbox{4-[2-(benzooxazol-2-ylamino]-8-chloro-2H-[1,2,4]triazolo[4,4]quinoxaline-1-one; \\ \mbox{4-[2-(benzooxazol-2-ylamino]-8-chloro-2H-[1,2,4]quinoxaline-1-one; \\ \mbox{4-[2-(benzooxazol-2-ylamino]-8-chloro-2H-[1,2,4]quinoxaline-1-one; \\ \mbox{4-[2-(benzooxazol-2-ylamino]-8-chloro-2H-[1,$ 

 $\label{lem:condition} \mbox{$4$-[2-(benzothiazol-2-ylamino)-ethylamino]-$8-bromo-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; $$ $$ (a.2.4)$ triazolo[4,3-a]quinoxaline-1-one; $$ (a.2.4)$ triazolo[4,3-a]qui$ 

 $\label{lem:condition} \mbox{$4$-[2-(benzothiazol-2-ylamino)-ethylamino]-$8$-chloro-$2$H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; $$ (a) $$ (a) $$-(a) $$-($ 

4-[2-(1H-benzothiazol-2-ylamino)-ethylamino]-8-fluoro-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

 $\label{lem:condition} \mbox{$4$-[2-(1H-benzoimidazol-2-y)-propylamino]-$8-fluoro-2H-[1,2,4]$ triazolo[4,3-a] quinoxaline-1-one; $$ (2-(1H-benzoimidazol-2-y)-propylamino]-$8-fluoro-2H-[1,2,4]$ triazolo[4,3-a] quinoxaline-1-one; $$ (2-(1H-benzoimidazol-2-y)-propylamino]-$8-fluoro-2-one; $$ (2-(1H-benzoimida$ 

2-[2-(8-fluoro-1-oxo-1,2-dihydro-[1,2,4]triazolo[4,3-a]quinoxalin-4-ylamino)-ethylamino]-isonicotinic acid;

 $\label{lem:condition} \mbox{$4$-[2-(6-methoxy-benzothiazol-2-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; \\ \mbox{$4$-[2-(6-methoxy-benzothiazol-2-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; \\ \mbox{$4$-[2-(6-methoxy-benzothiazol-2-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; \\ \mbox{$4$-[2-(6-methoxy-benzothiazol-2-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; \\ \mbox{$4$-[2-(6-methoxy-benzothiazol-2-ylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; \\ \mbox{$4$-[2-(6-methoxy-benzothiazol-2-ylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; \\ \mbox{$4$-[2-(6-methoxy-benzothiazol-2-ylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; \\ \mbox{$4$-[2-(6-methoxy-benzothiazol-2-ylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; \\ \mbox{$4$-[2-(6-methoxy-benzothiazol-2-ylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; \\ \mbox{$4$-[2-(6-methoxy-benzothiazol-2-ylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; \\ \mbox{$4$-[2-(6-methoxy-benzothiazol-2-ylamino]-2-ylamino]-2-ylaminoy-2-ylami$ 

8-bromo-4-[2-(1H-indol-3-yl)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; 8-fluoro-4-(tetrahydro-pyran-4-ylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; 8-fluoro-4-[2-(1H-indol-3-yl)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; 8-fluoro-4-[2-(pyridin-2-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; 8-fluoro-4-[2-(quinolin-2-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; 8-fluoro-4-[2-(quinolin-2-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one; 8-fluoro-4-[2-(2-trifluoromethyl-quinolin-4-ylamino)-ethylamino)-2H-[1,2,4]triazolo[4,3-a]

a]quinoxaline-1-one; 8-fluoro-4-[2-(3-trifluoromethyl-pyridin-2-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-

a]quinoxaline-1-one; 8-fluoro-4-12-(4-morpholin-4-vlmethyl-pyridin-2-ylamino)-ethylaminol-2H-I1.2-4ltriazolol4.3-

a]quinoxaline-1-one;

8-fluoro-4-[2-(4-trifluoromethyl-pyridin-2-ylamino)-ethylamino]-2H-[1,2,4]tiazolo[4,3-a]quinoxaline-1-one;

8-fluoro-4-[2-(4-trifluoromethyl-pyrimidin-2-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

8-fluoro-4-[2-(4-trifluoromethyl-pyridin-2-ylamino)-propylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

8-fluoro-4-[2-(5-cyano-pyridin-2-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

8-fluoro-4-[2-(5-trifluoromethyl-pyridin-2-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

8-fluoro-4-[2-(5-trifluoromethyl-pyridin-2-ylamino)-propylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

8-fluoro-4-[2-(6-methyl-5,6,7,8-tetrahydro-[1,6]naphthyridin-2-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

8-fluoro-4-[2-(6-trifluoromethyl-pyridin-2-ylamino)-ethy]-amino-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

8-fluoro-4-[2-(7-trifluoromethyl-quinolin-4-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

8-fluoro-4-[2-(8-trifluoromethyl-quinolin-4-ylamino)-ethylamino]-2H-[1,2,4]triazolo[4,3-a]quinoxaline-1-one;

8-fluoro-4-[3-(5-trifluoromethyl-pyridin-2-ylamino)-propylamino]-2H-[1,2,4]triazolo[4,3-alquinoxaline-1-one; or

1-oxo-4-[2-(4-trifluoromethyl-pyridin-2-ylamino)-ethylamino]-1,2-dihydro-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxylic acid methyl ester; or a pharmaceutically acceptable salt thereof.

 (Previously presented) A pharmaceutically composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, vehicle, or diluent

Claims 6-14. (Cancelled)

15. (New ): A compound of formula (I)

$$\mathbb{R}^{b}$$
 $\mathbb{N}$ 
 $\mathbb{N$ 

or a pharmaceutically acceptable salt thereof wherein:

Rais:

- (i) hydrogen;
- (ii) acetyl;
- (iii) -(C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally, and independently, substituted with from 1-3 of:
- (a) halogen; (b) -NR<sup>2</sup>R<sup>4</sup>; (c) -COR<sup>5</sup>; (d) -OR<sup>6</sup>; (e) aryl, optionally, and independently, substituted with from 1-3 of halogen; -(C<sub>1</sub>-C<sub>6</sub>)alkyt; or -(C<sub>1</sub>-C<sub>6</sub>)alkyt; (f) heteroaryl, optionally, and independently, substituted with from 1-3 of trifluoromethyl or -(C<sub>1</sub>-C<sub>6</sub>)alkyt; (d) -(C<sub>7</sub>-C<sub>1</sub>-c)cycloalkyt; or

(h)  $-(C_3-C_{11})$ heterocycloalkyl, optionally, and independently, substituted with from 1-3 of  $-(C_3-C_{11})$ heterocycloalkyl, optionally, and independently, substituted with from 1-3 of  $-(C_3-C_{11})$ heterocycloalkyl, or  $-(C_3-C_{11})$ hete

R<sup>b</sup> is:

(i) acetyl;

- (ii) -(C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally, and independently, substituted with from 1-3 of:
- (a) halogen; (b) -NR<sup>2</sup>R<sup>4</sup>; (c) -COR<sup>5</sup>; (d) -OR<sup>6</sup>; (e) aryl, optionally, and independently, substituted with from 1-3 of halogen; -(C<sub>1</sub>-C<sub>0</sub>)alkly; or -(C<sub>1</sub>-C<sub>0</sub>)alkloxy; (f) heteroaryl, optionally, and independently, substituted with from 1-3 of trifluoromethyl or -(C<sub>1</sub>-C<sub>0</sub>)alkyl; (g) -(C<sub>2</sub>-C<sub>1+1</sub>)cycloalkyl; or (h) -(C<sub>2</sub>-C<sub>1+1</sub>)heterocycloalkyl, optionally, and independently, substituted with from 1-3 of -(C<sub>1</sub>-C<sub>0</sub>)alkloxy; -(C<sub>1</sub>-C<sub>0</sub>)alkloxy;

R3 and R4 are independently:

(j) hydrogen; (k) amidino; (l) aryl, optionally, and independently, substituted with from 1-3 of halogen; cyano; nitro; -(C<sub>1</sub>-C<sub>0</sub>)alkyl, -(C<sub>1</sub>-C<sub>0</sub>)alkoy, or -COR<sup>5</sup>, (m) -(C<sub>1</sub>-C<sub>0</sub>)alkyl, optionally, and independently, substituted with from 1-3 of -(C<sub>3</sub>-C<sub>11</sub>)heterocycloalkyl; -(C<sub>3</sub>-C<sub>11</sub>)cycloalkyl; -(C<sub>1</sub>-C<sub>0</sub>)alkoxy, aryl; or heteroaryl; (n) heteroaryl, optionally, and independently, substituted with from 1-3 of halogen; trifluoromethyl; cyano; nitro; -COR<sup>5</sup>; -(C<sub>1</sub>-C<sub>0</sub>)alkyl, optionally substituted with -(C<sub>3</sub>-C<sub>11</sub>)heterocycloalkyl; or -(C<sub>1</sub>-C<sub>0</sub>)alkoxy, (o) -(C<sub>3</sub>-C<sub>11</sub>)heterocycloalkyl, optionally substituted with from 1-3 of -(C<sub>1</sub>-C<sub>0</sub>)alkyl; or (o) -COR<sup>5</sup>;

 $R^5$  is (q) hydroxy; (r) -(C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally, and independently, substituted with from 1-3 of -(C<sub>1</sub>-C<sub>6</sub>)alkoxy or aryl; (s) -(C<sub>1</sub>-C<sub>6</sub>)alkoxy; (t) heteroaryl; or (u) -(C<sub>3</sub>-C<sub>11</sub>)heterocycloalkyl, optionally substituted with from 1-3 of -(C<sub>1</sub>-C<sub>6</sub>)alkyl; and

 $R^6$  is (v) -( $C_1$ - $C_6$ )alkyl, optionally, and independently, substituted with from 1-3 of -( $C_1$ - $C_6$ )alkoxy or aryl; (w) heteroaryl; or (x) -( $C_3$ - $C_{11}$ )heterocycloalkyl, optionally substituted with from 1-3 of -( $C_1$ - $C_6$ )alkyl:

- (iv) -(C3-C11)cycloalkyl; or
- (v) -( $C_3$ - $C_{11}$ )heterocycloalkyl, optionally, and independently, substituted with from 1-3 of halogen; - $COR^5$ ; -( $C_1$ - $C_n$ )alkyl; and -( $C_1$ - $C_n$ )alkoxy; or

 $R^a$  and  $R^b$ , taken together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocycloalkyl ring, optionally having from 1-3 additional heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said 5- or 6-membered heterocycloalkyl ring is optionally, and independently, substituted with from 1-3 of halogen; -( $C_1$ - $C_0$ )alkyl; or heteroaryl, optionally, and independently, substituted with from 1-3 of halogen; rifflipromethyl; and cyano; and

 $R^1$  and  $R^2$  are independently selected from the group consisting of amino; halogen; hydrogen; trifluoromethyl; nitro; -COR $^5$ ; -NR $^3R^4$ ; -CONR $^3R^4$ ; and -(C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally, and

independently, substituted with from 1-3 of  $-(C_3 - C_{11})$ heterocycloalkyl;  $-NR^3R^4$ ; aryl; heteroaryl; or hvdroxy;

provided when Ra is hydrogen, and Rb is isopropyl, R1 is not F. Cl or Br.

16. (New) The compound of claim 15. wherein:

R<sup>a</sup> is hydrogen;

 $R^5$  is selected from the group consisting of (iii)  $\neg (C_1 \neg C_9)$  alkyl, optionally substituted with: (b)  $\neg NR^3R^3$ , wherein  $R^3$  is hydrogen and  $R^4$  is heteroaryl, optionally, and independently, substituted with from 1-3 of trifluoromethyl; cyano;  $\neg (C_1 \neg C_9)$  alkyl, optionally substituted with  $\neg (C_3 \neg C_1)$  heterocycloalkyl;  $\neg (C_1 \neg C_9)$  alkoxy; or  $\neg COR^5$ ; (e) aryl, optionally substituted with from 1-3 halogen atoms; (f) heteroaryl; (h)  $\neg (C_3 \neg C_1)$  heterocycloalkyl; (iv)  $\neg (C_3 \neg C_1)$  heteroc

 $R^1$  is hydrogen; halogen; -COR $^5$ ; -CONR $^3$ R $^4$ ; or -( $C_1$ - $C_0$ )alkyl, optionally, and independently, substituted with from 1-3 of -( $C_3$ - $C_1$ -)heterocycloalkyl or -NR $^3$ R $^4$ ; and

R<sup>2</sup> is hydrogen; -CONR<sup>3</sup>R<sup>4</sup>, or -(C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally, and independently, substituted with from 1-3 of -(C<sub>2</sub>-C<sub>11</sub>)heterocycloalkyl or -NR<sup>3</sup>R<sup>4</sup>.

17. (New) The compound of claim 15. wherein:

Ra is hydrogen:

 $R^b \text{ is (iii) -(C_1-C_3)alkyl, optionally substituted with (b) -NR^3R^4, wherein \ R^3 \text{ is hydrogen and} \\ R^4 \text{ is heteroaryl, optionally, and independently, substituted with from 1-3 of trifluoromethyl; cyano; - (C_1-C_6)alkyl, optionally substituted with -(C_3-C_1)heterocycloalkyl; or -(C_1-C_6)alkoxy; (e) aryl; (f) heteroaryl; (h) -(C_3-C_6)heterocycloalkyl; (iv) -(C_3-C_6)cycloalkyl; or (v) -(C_3-C_1)heterocycloalkyl; (iv) -(C_3-C_6)cycloalkyl; or (v) -(C_3-C_1)heterocycloalkyl; or (v) -(C$ 

 $R^1$  is hydrogen; fluoro; chloro; bromo; -COR $^5$ , wherein  $R^5$  is hydroxy or -( $C_1$ - $C_e$ )alkoxy; or -CONR $^3$ R $^4$ , wherein R $^3$  is hydrogen or -( $C_1$ - $C_e$ )alkyl; and R $^4$  is -( $C_1$ - $C_e$ )alkyl, optionally substituted with -( $C_1$ - $C_e$ )alkoxy; and

 $R^2 \ \text{is hydrogen or -CONR}^3 R^4, \ \text{wherein } R^3 \ \text{is -(C_1-C_6)alkyl; and } R^4 \ \text{is -(C_1-C_6)alkyl, optionally substituted with -(C_1-C_6)alkoxy.}$ 

18. (New) A pharmaceutically composition comprising the compound of claim 15, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, vehicle, or diluent.